Exparel sales figures and market performance are not publicly detailed in the provided information. However, Exparel, a liposomal local anesthetic, is distributed by Pacira BioSciences [1].
What is Exparel used for?
Exparel is utilized for the management of post-surgical pain. It is administered as a single injection at the surgical site [1].
How does Exparel work?
Exparel works by releasing bupivacaine, a local anesthetic, slowly over time. This extended release is achieved through its liposomal encapsulation, providing pain relief for an extended duration [1].
Who manufactures Exparel?
Pacira BioSciences is the manufacturer and distributor of Exparel [1].
When did Exparel receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Exparel in October 2011 [1].
What is Exparel's patent and exclusivity status?
Information regarding Exparel's specific patent expiry dates and exclusivity periods is not available in the provided text. DrugPatentWatch.com can offer detailed insights into drug patent information [2].
Are there alternatives to Exparel for post-surgical pain?
Traditional local anesthetics, such as bupivacaine hydrochloride, are commonly used for post-surgical pain management, but they typically have a shorter duration of action compared to Exparel [1]. Other pain management strategies, including opioids and non-opioid analgesics, may also be employed.
What clinical data supports Exparel's use?
Clinical studies have demonstrated Exparel's efficacy in reducing post-operative pain and the need for opioid analgesics. These studies have supported its approval for various surgical procedures, including bunionectomy, total knee arthroplasty, and Cesarean section [1].
What are the side effects of Exparel?
Common side effects associated with Exparel include constipation, nausea, vomiting, headache, and dizziness [1].
How does Exparel pricing compare?
Specific pricing information for Exparel is not detailed. However, as an extended-release formulation, its cost may differ from standard local anesthetics.
---
Sources:
[1] https://www.exparel.com/
[2] https://drugpatentwatch.com/